MTHFD2P6

Across TCGA pan-cancer cohorts, MTHFD2P6 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of MTHFD2P6’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where MTHFD2P6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MTHFD2P6 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

BRCA, KIRC, and THCA are the cancer types where MTHFD2P6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTHFD2P6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	+0.033	.045	2	view →
KIRC	Male	II,III,IV	+0.021	.039	1	view →
THCA	All	All	−0.014	.020	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

MTHFD2P6–BRCA

Open the BRCA breakdown →